TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 2883677

Group type: EXPERIMENTAL
Intervention: 25 mg zotepine
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: 50 mg zotepine
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: 100 mg zotepine
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: 50 mg clozapine
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: 100 mg clozapine
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: CFF, skin conductance, pupillary diameter and pupillary response measurements after both compounds
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Pulse rate
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Blood pressure
Number of subjects: 15
Study: 30747632

Group type: EXPERIMENTAL
Intervention: Lichtenstein hernioplasty
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: TAPP hernioplasty
Number of subjects: 122
Study: 27098404

Group type: EXPERIMENTAL
Intervention: Ustekinumab 45 mg or 90 mg
Number of subjects: 256

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 256
Study: 26089047

Group type: EXPERIMENTAL
Intervention: Apremilast 30 mg twice a day
Number of subjects: 844

Group type: EXPERIMENTAL
Intervention: Apremilast (after switching from placebo at week 16)
Number of subjects: 844

Group type: COMPARATOR
Intervention: Placebo (initially randomized group)
Number of subjects: 844

Group type: COMPARATOR
Intervention: Placebo (after switching to apremilast at week 32)
Number of subjects: 844

Group type: EXPERIMENTAL
Intervention: Apremilast (weeks 32-52)
Number of subjects: 844

Group type: COMPARATOR
Intervention: Apremilast and Placebo (during the placebo-controlled period)
Number of subjects: 844
Study: 23053769

Group type: EXPERIMENTAL
Intervention: Intravitreal clindamycin plus dexamethasone (IVCD)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Conventional oral therapy (COT) including pyrimethamine, sulfadiazine, folinic acid and prednisone
Number of subjects: 66

Group type: COMPARATOR
Intervention: Conventional oral therapy (COT)
Number of subjects: 66
Study: 21770716

Group type: EXPERIMENTAL
Intervention: DPSGC 25 mg
Number of subjects: 514

Group type: EXPERIMENTAL
Intervention: DPSGC 50 mg
Number of subjects: 514

Group type: EXPERIMENTAL
Intervention: DPSGC 100 mg
Number of subjects: 514

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 514
Study: 19487635

Group type: EXPERIMENTAL
Intervention: Subcutaneous insulin infusion at 0.5 units/h
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Subcutaneous insulin infusion at 1.0 units/h
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Subcutaneous insulin infusion at 2.0 units/h
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Subcutaneous insulin infusion at 0.5, 1.0, and 2.0 units/h
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Subcutaneous insulin infusion at 1.0 and 2.0 units/h
Number of subjects: 10
Study: 16685042

Group type: EXPERIMENTAL
Intervention: 26% carbohydrate, low saturated fat diet
Number of subjects: 178

Group type: COMPARATOR
Intervention: 54% carbohydrate diet
Number of subjects: 178

Group type: EXPERIMENTAL
Intervention: 26% carbohydrate diet with higher saturated fat intake
Number of subjects: 178
Study: 15292628

Group type: EXPERIMENTAL
Intervention: Group life review activities
Number of subjects: 80

Group type: COMPARATOR
Intervention: Discussion activities about health (Control)
Number of subjects: 80
Study: 11412294

Group type: EXPERIMENTAL
Intervention: Pressure-controlled inverse ratio ventilation
Number of subjects: 10

Group type: COMPARATOR
Intervention: Controlled mechanical ventilation
Number of subjects: 10
Study: 9505133

Group type: EXPERIMENTAL
Intervention: Lead stimulus‐blink stimulus pairings with a lead interval of 120 ms and 2000 ms
Number of subjects: 128

Group type: COMPARATOR
Intervention: Lead stimulus change (pitch change)
Number of subjects: 128
Study: 7977180

Group type: EXPERIMENTAL
Intervention: Group condition (G) - received self-help manuals, watched a 20-day televised series, participated in six sessions emphasizing quitting techniques and social support, and monthly peer-led support groups with incentives.
Number of subjects: 38

Group type: COMPARATOR
Intervention: Nongroup condition (NG) - received self-help manuals and watched a 20-day televised series, but no further treatment after the initial phase.
Number of subjects: 38
Study: 2489863

Group type: EXPERIMENTAL
Intervention: Static stretching of the quadriceps muscle group before a step test
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Stepping warm-up only
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Both stretching and stepping warm-up prior to a step test
Number of subjects: 62

Group type: COMPARATOR
Intervention: Step test only (control group)
Number of subjects: 62
Study: 30475746

Group type: EXPERIMENTAL
Intervention: Cranial electrotherapy stimulation (CES) with Alpha‐Stim 100
Number of subjects: 40

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 40
Study: 27609816

Group type: EXPERIMENTAL
Intervention: F-18-fluorodeoxyglucose PET-assisted management
Number of subjects: 392

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 392

Group type: EXPERIMENTAL
Intervention: F-18-fluorodeoxyglucose PET-assisted management (adherence to recommendations)
Number of subjects: 392
Study: 23988131

Group type: EXPERIMENTAL
Intervention: anodal transcranial direct current stimulation (atDCS)
Number of subjects: 40

Group type: COMPARATOR
Intervention: sham stimulation
Number of subjects: 40
Study: 22849414

Group type: EXPERIMENTAL
Intervention: Message that intelligence grows over time
Number of subjects: 36

Group type: COMPARATOR
Intervention: Message that intelligence is static
Number of subjects: 36
Study: 20819898

Group type: COMPARATOR
Intervention: Iron supplementation at 0 mg/kg per day (placebo)
Number of subjects: 285

Group type: EXPERIMENTAL
Intervention: Iron supplementation at 1 mg/kg per day
Number of subjects: 285

Group type: EXPERIMENTAL
Intervention: Iron supplementation at 2 mg/kg per day
Number of subjects: 285
Study: 18284506

Group type: EXPERIMENTAL
Intervention: Selective pulmonary vein isolation (SePVI)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Empirical four pulmonary vein isolation (EmPVI)
Number of subjects: 77
Study: 16168734

Group type: EXPERIMENTAL
Intervention: Affected Hand (AH)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Non-Affected Hand (NAH)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Control Group
Number of subjects: 19
Study: 12706640

Group type: EXPERIMENTAL
Intervention: ARDS patients
Number of subjects: 55

Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 55
Study: 10674681

Group type: COMPARATOR
Intervention: Fansidar (3 tablets, 75 mg of pyrimethamine and 1,500 mg of sulfadoxine, a single dose on the first day)
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Fansidar (3 tablets, 75 mg of pyrimethamine and 1,500 mg of sulfadoxine, a single dose on the first day) plus primaquine (30 mg a day for 14 days)
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Primaquine (30 mg a day for 14 days)
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Artesunate (200 mg once a day for 3 days) plus primaquine (30 mg a day for 14 days)
Number of subjects: 92
Study: 2404389

Group type: EXPERIMENTAL
Intervention: Brief infusion of intravenous heparin for less than or equal to 24 hours (group 1)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Prolonged infusion of intravenous heparin for greater than or equal to 72 hours (group 2)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 50
Study: 216238

Group type: EXPERIMENTAL
Intervention: Postoperative irradiation
Number of subjects: 108

Group type: COMPARATOR
Intervention: Control group (only operated upon)
Number of subjects: 108
Study: 29676197

Group type: EXPERIMENTAL
Intervention: Test formulation of strontium ranelate
Number of subjects: 36

Group type: COMPARATOR
Intervention: Reference formulation of strontium ranelate
Number of subjects: 36
Study: 27759067

Group type: EXPERIMENTAL
Intervention: Weight loss interventions (low-calorie diet and bariatric surgery)
Number of subjects: 50
Study: 24960665

Group type: EXPERIMENTAL
Intervention: PCR-SSP
Number of subjects: 370

Group type: EXPERIMENTAL
Intervention: PCR-RFLP
Number of subjects: 370

Group type: EXPERIMENTAL
Intervention: RQ-PCR
Number of subjects: 370

Group type: EXPERIMENTAL
Intervention: All methods
Number of subjects: 370
Study: 23602131

Group type: EXPERIMENTAL
Intervention: Hair testosterone measurement in men (n=24)
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Hair testosterone measurement in women (n=49)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Hair testosterone levels comparison
Number of subjects: 73
Study: 21036891

Group type: EXPERIMENTAL
Intervention: Sildenafil (50 mg three times per day)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study: 18840769

Group type: EXPERIMENTAL
Intervention: Bright Bodies program (intensive lifestyle program)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Clinic-care control
Number of subjects: 23
Study: 17594298

Group type: EXPERIMENTAL
Intervention: Analgesics
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Recommended fluid intake
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Emesis
Number of subjects: 76
Study: 15198635

Group type: EXPERIMENTAL
Intervention: Alphabet cues
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Combined topic and alphabet cues
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Topic cues
Number of subjects: 7

Group type: COMPARATOR
Intervention: Habitual speech (control condition)
Number of subjects: 7
Study: 12066084

Group type: EXPERIMENTAL
Intervention: Supracervical Foley catheter and intravaginal dinoprostone gel
Number of subjects: 339

Group type: EXPERIMENTAL
Intervention: Supracervical Foley catheter and 100 microg oral doses of misoprostol
Number of subjects: 339

Group type: EXPERIMENTAL
Intervention: Serial 100‐microg oral doses of misoprostol
Number of subjects: 339

Group type: COMPARATOR
Intervention: All groups
Number of subjects: 339
Study: 9831997

Group type: EXPERIMENTAL
Intervention: Sertraline hydrochloride (n = 77) in flexible doses up to 200 mg
Number of subjects: 161

Group type: COMPARATOR
Intervention: Placebo (n = 84)
Number of subjects: 161
Study: 7521313

Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid 150 mg/day
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid 600 mg/day
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid 900 mg/day
Number of subjects: 76

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 76
Study: 2653621

Group type: EXPERIMENTAL
Intervention: Fenofibrate
Number of subjects: 227
Study: 117493

Group type: EXPERIMENTAL
Intervention: Naloxone
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control and anxiety levels
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Stress levels
Number of subjects: 16
Study: 31630035

Group type: EXPERIMENTAL
Intervention: Celecoxib (CBX) adjunctive treatment
Number of subjects: 47

Group type: COMPARATOR
Intervention: Placebo (PBO)
Number of subjects: 47
Study: 30885268

Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 27613646

Group type: EXPERIMENTAL
Intervention: Social self-value empowerment intervention (six weekly sessions)
Number of subjects: 132

Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 132
Study: 26391131

Group type: EXPERIMENTAL
Intervention: hsCRP >3 mg/L
Number of subjects: 10456

Group type: COMPARATOR
Intervention: hsCRP <1 mg/L
Number of subjects: 10456
Study: 24259978

Group type: EXPERIMENTAL
Intervention: 25 mg AMT before bedtime
Number of subjects: 34

Group type: COMPARATOR
Intervention: 40 mg Pantoprazole once daily for 4 weeks
Number of subjects: 34
Study: 22309474

Group type: EXPERIMENTAL
Intervention: 10-week psychosocial treatment involving parent management training for ADHD and family-based cognitive-behavioral therapy for anxiety.
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 10-week psychosocial treatment
Number of subjects: 8

Group type: COMPARATOR
Intervention: Baseline control conditions (2, 3, or 4 weeks)
Number of subjects: 8
Study: 20195183

Group type: COMPARATOR
Intervention: Cycling (CYC; 60 min, 70% V˙O2peak)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Resistance (REX; 8 x 5 leg extension, 80% one‐repetition maximum, 3‐min recovery)
Number of subjects: 16
Study: 17646509

Group type: EXPERIMENTAL
Intervention: Dexamethasone 16 mg IV
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 16254089

Group type: EXPERIMENTAL
Intervention: Prenegotiation affective trust
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Postnegotiation cognitive trust
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Affective trust
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Interest turning points
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Negative characterization turning points
Number of subjects: 0
Study: 12190056

Group type: EXPERIMENTAL
Intervention: Theory-based direct mail campaign
Number of subjects: 424

Group type: COMPARATOR
Intervention: Control group (comparison group)
Number of subjects: 424
Study: 10442276

Group type: EXPERIMENTAL
Intervention: Gabapentin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Acetaminophen (Control)
Number of subjects: 0
Study: 7884951

Group type: EXPERIMENTAL
Intervention: 5 mg/kg of ibuprofen
Number of subjects: 84192

Group type: EXPERIMENTAL
Intervention: 10 mg/kg of ibuprofen
Number of subjects: 84192

Group type: COMPARATOR
Intervention: 12 mg/kg of acetaminophen
Number of subjects: 84192
Study: 2403997

Group type: EXPERIMENTAL
Intervention: Oral physostigmine
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 6453432

Group type: EXPERIMENTAL
Intervention: Concise Enamel Bond
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Concise White Sealant
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Clearfil Bonding Agent
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Estilux Glaze
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Uvio Seal
Number of subjects: 64
Study: 30559054

Group type: EXPERIMENTAL
Intervention: Oleogel‐S10
Number of subjects: 61

Group type: COMPARATOR
Intervention: Octenilin® wound gel
Number of subjects: 61
Study: 28132813

Group type: EXPERIMENTAL
Intervention: LSD (lysergic acid diethylamide)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ketanserin (5-HT2AR antagonist)
Number of subjects: 0
Study: 25181938

Group type: EXPERIMENTAL
Intervention: Music therapy and progressive muscle relaxation training plus routine nursing care
Number of subjects: 170

Group type: COMPARATOR
Intervention: Routine nursing care
Number of subjects: 170
Study: 23740894

Group type: EXPERIMENTAL
Intervention: CCRT (3 cycles of carboplatin and 5‐fluorouracil plus conventional radiotherapy, 66 Gy in 6.5 weeks)
Number of subjects: 85

Group type: COMPARATOR
Intervention: CCB (hybrid accelerated radiotherapy, 70 Gy in 6 weeks)
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: CCRT
Number of subjects: 85

Group type: COMPARATOR
Intervention: CCB
Number of subjects: 85
Study: 21384392

Group type: EXPERIMENTAL
Intervention: Low-level laser treatments on one side of the body three times per week for 2 weeks
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Weight loss supplement (Curva™) in conjunction with low-level laser treatments
Number of subjects: 5

Group type: COMPARATOR
Intervention: Physician blinded photo evaluation
Number of subjects: 5

Group type: COMPARATOR
Intervention: Satisfaction questionnaires
Number of subjects: 5

Group type: COMPARATOR
Intervention: Ultrasound measurements
Number of subjects: 5
Study: 19928389

Group type: EXPERIMENTAL
Intervention: Sleeping at 0 degrees to 45 degrees
Number of subjects: 25
Study: 17013479

Group type: EXPERIMENTAL
Intervention: Metronidazole (pre and postoperative)
Number of subjects: 200

Group type: COMPARATOR
Intervention: No medications (control group)
Number of subjects: 200
Study: 15464863

Group type: EXPERIMENTAL
Intervention: drugs + rTMS (1 Hz, 0.6 T, 100 stimuli per day for 7 days, repeated at least twice yearly for 3 years)
Number of subjects: 2

Group type: COMPARATOR
Intervention: drugs only
Number of subjects: 2
Study: 11417923

Group type: EXPERIMENTAL
Intervention: Fluoxetine + Melatonin
Number of subjects: 35

Group type: COMPARATOR
Intervention: Fluoxetine + Placebo
Number of subjects: 35
Study: 9236640

Group type: COMPARATOR
Intervention: 0 mg rhRIx
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: 1 mg rhRIx
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: 2 mg rhRIx
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: 4 mg rhRIx
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: All treatment groups
Number of subjects: 96
Study: 7963141

Group type: EXPERIMENTAL
Intervention: Casein-based high-degree hydrolysate (CHy)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Soy formula (SF)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Whey-based low-degree hydrolysate (WHy)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: All formula-fed infants
Number of subjects: 82
Study: 2821217

Group type: EXPERIMENTAL
Intervention: Cognitive methods of pain control training
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Placebo medication
Number of subjects: 0

Group type: COMPARATOR
Intervention: No intervention
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Naloxone (opiate antagonist)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Saline solution
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cognitive methods of pain control with naloxone
Number of subjects: 0
Study: 29170936

Group type: EXPERIMENTAL
Intervention: Naturalistic developmental behavioral intervention with speech generating device
Number of subjects: 58

Group type: COMPARATOR
Intervention: Naturalistic developmental behavioral intervention without speech generating device
Number of subjects: 58
Study: 27346650

Group type: EXPERIMENTAL
Intervention: Physical training and nutritional intervention (PTN)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Social support intervention (SoSu)
Number of subjects: 80
Study: 25052161

Group type: EXPERIMENTAL
Intervention: YXBCM01 granule (5.5 g twice daily)
Number of subjects: 600

Group type: COMPARATOR
Intervention: Topical therapy (calcipotriol betamethasone for the first 4 weeks and calcipotriol ointment for the remaining 8 weeks)
Number of subjects: 600
Study: 23450320

Group type: EXPERIMENTAL
Intervention: Multifamily group treatment for TBI
Number of subjects: 14
Study: 20638322

Group type: EXPERIMENTAL
Intervention: Multimodal group rehabilitation
Number of subjects: 14

Group type: COMPARATOR
Intervention: Usual care physiotherapy
Number of subjects: 14
Study: 19418093

Group type: EXPERIMENTAL
Intervention: Diathermy incision (group A)
Number of subjects: 369

Group type: COMPARATOR
Intervention: Scalpel incision (group B)
Number of subjects: 369
Study: 16260436

Group type: EXPERIMENTAL
Intervention: Demonstration of infant reflexes, attention, motor skills, and sleep-wake states (Group 1, n = 28)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Viewing educational materials (Group 2, n = 31)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Informal discussion (Control Group 3, n = 25)
Number of subjects: 84
Study: 12100060

Group type: EXPERIMENTAL
Intervention: prednisolone 30 mg/day
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: fluticasone propionate 1000 microg/day b.i.d.
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: fluticasone propionate 250 microg/day b.i.d.
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: High sputum eosinophils (> or = 3%)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Eosinophils in blood or sputum
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Smoking status
Number of subjects: 120
Study: 10067139

Group type: EXPERIMENTAL
Intervention: Symptom-focused task
Number of subjects: 70

Group type: COMPARATOR
Intervention: Distracting task
Number of subjects: 70
Study: 7717714

Group type: EXPERIMENTAL
Intervention: 5‐fluorouracil (5‐FU) 600 mg/m2 plus high‐dose l‐leucovorin (l‐LV) 250 mg/m2, given weekly by i.v. injection
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: 5‐fluorouracil (5‐FU) 370 mg/m2 plus high‐dose l‐leucovorin (l‐LV) 100 mg/m2, given simultaneously for 5 consecutive days
Number of subjects: 122

Group type: COMPARATOR
Intervention: 5‐fluorouracil (5‐FU) 370 mg/m2 plus low‐dose l‐leucovorin (l‐LV) 10 mg/m2, given with the same schedule as regimen B
Number of subjects: 122
Study: 1790311

Group type: EXPERIMENTAL
Intervention: Pentacard 20 mg tablets
Number of subjects: 12

Group type: COMPARATOR
Intervention: Ismo 20 mg tablets
Number of subjects: 12
Study: 7248480

Group type: EXPERIMENTAL
Intervention: Fixed combination (Inderetic) of 80 mg propranolol twice daily and 2.5 mg bendrofluazide twice daily
Number of subjects: 12

Group type: COMPARATOR
Intervention: Free combination of 80 mg propranolol twice daily and 2.5 mg bendrofluazide twice daily
Number of subjects: 12
Study: 30826050

Group type: EXPERIMENTAL
Intervention: Clopidogrel loading dose (LD)
Number of subjects: 802

Group type: COMPARATOR
Intervention: No loading dose (NLD)
Number of subjects: 802

Group type: EXPERIMENTAL
Intervention: Clopidogrel maintenance therapy
Number of subjects: 802

Group type: COMPARATOR
Intervention: No clopidogrel maintenance therapy
Number of subjects: 802
Study: 28827938

Group type: EXPERIMENTAL
Intervention: Honey (20 mL)
Number of subjects: 82

Group type: COMPARATOR
Intervention: 0.9% saline (control)
Number of subjects: 82
Study: 25399224

Group type: EXPERIMENTAL
Intervention: Site-specific disinfection method using Listerine Cool Mint mouth rinse
Number of subjects: 20

Group type: COMPARATOR
Intervention: Traditional panoral rinsing method using Listerine Cool Mint mouth rinse
Number of subjects: 20
Study: 23061313

Group type: EXPERIMENTAL
Intervention: Group Motivational Interviewing plus Brief Cognitive Behavior Therapy (GMI‐BCBT) plus usual care
Number of subjects: 200

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 200
Study: 19238802

Group type: EXPERIMENTAL
Intervention: XP13512 1800 mg/day
Number of subjects: 38
Study: 16380286

Group type: EXPERIMENTAL
Intervention: Lumbar spine mobilization, exercise, and slump stretching
Number of subjects: 30

Group type: COMPARATOR
Intervention: Lumbar spine mobilization and exercise
Number of subjects: 30
Study: 12514593

Group type: EXPERIMENTAL
Intervention: Reversed saphenous venous bypass
Number of subjects: 151

Group type: COMPARATOR
Intervention: Polytetrafluoroethylene bypass
Number of subjects: 151